NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Clinical Trials
44 trialsNCT02945800 2026-04-02
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04383119 2026-03-25
ISG-ARTICLE
Italian Sarcoma Group
Phase 2 Recruiting
NCT07359053 2026-01-22
MAGNATE-S
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT03449901 2025-12-11
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT04807816 2025-10-02
TARSARC
Institut Bergonié
Phase 2 Recruiting
NCT05275426 2025-08-15
A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06114004 2025-06-25
SeliSarc
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Phase 2 Recruiting
NCT04535271 2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT02203760 2024-11-15
PazoDoble
North Eastern German Society of Gynaecological Oncology
Phase 2 Active not recruiting
NCT04183062 2024-11-08
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Phase 2 Withdrawn
NCT04535713 2024-07-05
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT06114225 2023-11-02
PROMIS
Ruijin Hospital
Phase 2 Recruiting
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT03810976 2022-06-16
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Yonsei University
Phase 2 Completed
NCT05116800 2021-12-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Phase 2 Withdrawn
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT04906876 2021-07-28
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Phase 2 Withdrawn
NCT02448537 2021-03-03
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Massachusetts General Hospital
Phase 2 Completed
NCT03468075 2020-12-10
Gemcitabine Plus Ascorbate for Sarcoma in Adults
University of Iowa
Phase 2 Terminated
NCT00860015 2020-08-25
Alimta Plus Gemcitabine for Advanced Sarcoma
Columbia University
Phase 2 Completed
NCT01593748 2020-04-06
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
Phase 2 Completed
NCT01442662 2020-01-31
LMS03
UNICANCER
Phase 2 Completed
NCT01574716 2019-08-21
SOURCE
Morphotek
Phase 2 Completed
NCT02718482 2019-05-13
OsteoREC2015
Italian Sarcoma Group
Phase 2 Terminated
NCT02303262 2019-01-29
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00114218 2019-01-08
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
GOG Foundation
Phase 2 Completed
NCT02249702 2017-12-06
TAUL
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT00031629 2016-12-08
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
GOG Foundation
Phase 2 Completed
NCT00227669 2016-08-30
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
UNICANCER
Phase 2 Completed
NCT00887809 2016-01-25
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02429973 2015-04-29
GEIS-29
Broto, Javier MartÃn, M.D.
Phase 2 Completed
NCT00282087 2014-12-01
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00101127 2014-02-14
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
GOG Foundation
Phase 2 Completed
NCT00359333 2013-10-30
STS
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT00003316 2013-04-11
Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
GOG Foundation
Phase 2 Terminated
NCT01812018 2013-03-15
Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
ChineseAMS
Phase 2 Unknown
NCT00004066 2013-03-07
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00073983 2012-03-12
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00407433 2009-08-07
Clinical Studies of Gemcitabine-Oxaliplatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT00807261 2008-12-12
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Asan Medical Center
Phase 2 Unknown
NCT00134641 2007-12-21
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed